Orlistat-associated adverse effects and drug interactions: a critical review.

@article{Filippatos2008OrlistatassociatedAE,
  title={Orlistat-associated adverse effects and drug interactions: a critical review.},
  author={Theodosios D Filippatos and Christos S. Derdemezis and Irene F. Gazi and Eleni S Nakou and Dimitri P. Mikhailidis and Moses S Elisaf},
  journal={Drug safety},
  year={2008},
  volume={31 1},
  pages={53-65}
}
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use may be associated with less well known, but sometimes clinically relevant, adverse effects. More specifically, the use of orlistat has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain… CONTINUE READING
75 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

Similar Papers

Loading similar papers…